Regencell Bioscience Holdings Limited (RGC)
USD 36.67
(29.85%)
USD 36.67
(29.85%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -2.9 Million USD | -161.14% |
| 2023 | -1.1 Million USD | 80.5% |
| 2022 | -5.64 Million USD | -255.85% |
| 2021 | 3.62 Million USD | 35.02% |
| 2020 | 2.68 Million USD | 45.93% |
| 2019 | 1.83 Million USD | -99.91% |
| 2018 | 2.13 Billion USD | 8.15% |
| 2017 | 1.97 Billion USD | -2.95% |
| 2016 | 2.03 Billion USD | -3.88% |
| 2015 | 2.11 Billion USD | 0.0% |
| 2013 | 1.93 Billion USD | 6.12% |
| 2012 | 1.82 Billion USD | 2.05% |
| 2011 | 1.78 Billion USD | 13.06% |
| 2010 | 1.58 Billion USD | 9985.0% |
| 2009 | -16 Million USD | 0.0% |
| 2007 | 1.42 Billion USD | -16.87% |
| 2006 | 1.71 Billion USD | 4.31% |
| 2005 | 1.64 Billion USD | 108.87% |
| 2004 | 789 Million USD | 0.0% |
| 2002 | 285 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -4.8 Million USD | -335.92% |
| 2024 Q2 | -4.8 Million USD | 0.0% |
| 2024 Q4 | -2.9 Million USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 Q4 | -1.1 Million USD | 28.47% |
| 2023 FY | -1.1 Million USD | 80.5% |
| 2023 Q3 | -1.53 Million USD | 0.0% |
| 2022 Q4 | -5.64 Million USD | 6.79% |
| 2022 FY | -5.64 Million USD | -255.85% |
| 2022 Q3 | -6.05 Million USD | -444200.39% |
| 2022 Q1 | 1.36 Million USD | -62.35% |
| 2022 Q2 | 1363.82 USD | -99.9% |
| 2021 Q1 | 3.23 Million USD | 20.65% |
| 2021 FY | 3.62 Million USD | 35.02% |
| 2021 Q4 | 3.62 Million USD | 0.0% |
| 2021 Q2 | 3.23 Million USD | 0.0% |
| 2021 Q3 | 3.62 Million USD | 11.91% |
| 2020 Q3 | 2.68 Million USD | 0.0% |
| 2020 Q1 | 243.3 Thousand USD | 0.0% |
| 2020 FY | 2.68 Million USD | 45.93% |
| 2020 Q4 | 2.68 Million USD | 0.0% |
| 2019 FY | 1.83 Million USD | -99.91% |
| 2018 Q1 | 2.17 Billion USD | 2.08% |
| 2018 Q2 | 2.13 Billion USD | -1.94% |
| 2018 FY | 2.13 Billion USD | 8.15% |
| 2017 Q4 | 2.13 Billion USD | 17.79% |
| 2017 Q1 | 2.03 Billion USD | 5.12% |
| 2017 Q2 | 1.97 Billion USD | -2.89% |
| 2017 Q3 | 1.81 Billion USD | -8.28% |
| 2017 FY | 1.97 Billion USD | -2.95% |
| 2016 Q1 | 2.15 Billion USD | 8.27% |
| 2016 FY | 2.03 Billion USD | -3.88% |
| 2016 Q4 | 1.93 Billion USD | 2.2% |
| 2016 Q3 | 1.89 Billion USD | -6.97% |
| 2016 Q2 | 2.03 Billion USD | -5.71% |
| 2015 FY | 2.11 Billion USD | 0.0% |
| 2015 Q1 | 2.02 Billion USD | 5.6% |
| 2015 Q4 | 1.99 Billion USD | -4.55% |
| 2015 Q3 | 2.08 Billion USD | -1.36% |
| 2015 Q2 | 2.11 Billion USD | 4.45% |
| 2014 Q2 | 1.93 Billion USD | -0.23% |
| 2014 Q4 | 1.92 Billion USD | -0.81% |
| 2014 Q3 | 1.93 Billion USD | -0.02% |
| 2014 Q1 | 1.94 Billion USD | 0.93% |
| 2013 FY | 1.93 Billion USD | 6.12% |
| 2013 Q4 | 1.92 Billion USD | 7.88% |
| 2013 Q2 | 1.82 Billion USD | 8.27% |
| 2013 Q3 | 1.78 Billion USD | -2.31% |
| 2013 Q1 | 1.68 Billion USD | 4.41% |
| 2012 Q2 | 1.69 Billion USD | -4.32% |
| 2012 FY | 1.82 Billion USD | 2.05% |
| 2012 Q4 | 1.61 Billion USD | -0.74% |
| 2012 Q3 | 1.62 Billion USD | -3.92% |
| 2012 Q1 | 1.76 Billion USD | 0.91% |
| 2011 Q2 | 1.78 Billion USD | 7.77% |
| 2011 Q1 | 1.65 Billion USD | -0.57% |
| 2011 Q3 | 1.82 Billion USD | 2.26% |
| 2011 FY | 1.78 Billion USD | 13.06% |
| 2011 Q4 | 1.75 Billion USD | -4.13% |
| 2010 Q1 | -61 Million USD | 46.96% |
| 2010 Q3 | -193 Million USD | -112.2% |
| 2010 Q4 | 1.66 Billion USD | 964.66% |
| 2010 Q2 | 1.58 Billion USD | 2692.79% |
| 2010 FY | 1.58 Billion USD | 9985.0% |
| 2009 FY | -16 Million USD | 0.0% |
| 2009 Q1 | 1.81 Billion USD | 6.2% |
| 2009 Q2 | -16 Million USD | -100.88% |
| 2009 Q3 | -53 Million USD | -231.25% |
| 2009 Q4 | -115 Million USD | -116.98% |
| 2008 Q4 | 1.7 Billion USD | 15.32% |
| 2008 Q2 | 1.42 Billion USD | -3.84% |
| 2008 Q3 | 1.48 Billion USD | 3.71% |
| 2008 Q1 | 1.48 Billion USD | 1.36% |
| 2007 Q4 | 1.46 Billion USD | 37.01% |
| 2007 FY | 1.42 Billion USD | -16.87% |
| 2007 Q3 | 1.07 Billion USD | -37.75% |
| 2007 Q2 | 1.71 Billion USD | -2.83% |
| 2007 Q1 | 1.76 Billion USD | 5.36% |
| 2006 Q4 | 1.67 Billion USD | -1.76% |
| 2006 Q3 | 1.7 Billion USD | 1.97% |
| 2006 Q2 | 1.67 Billion USD | -6.68% |
| 2006 Q1 | 1.79 Billion USD | 0.3% |
| 2006 FY | 1.71 Billion USD | 4.31% |
| 2005 Q2 | 1.64 Billion USD | -10.26% |
| 2005 FY | 1.64 Billion USD | 108.87% |
| 2005 Q1 | 1.83 Billion USD | 19.33% |
| 2005 Q3 | 1.69 Billion USD | 2.65% |
| 2005 Q4 | 1.79 Billion USD | 5.85% |
| 2004 FY | 789 Million USD | 0.0% |
| 2004 Q2 | 789 Million USD | -15.8% |
| 2004 Q1 | 937 Million USD | 382.99% |
| 2004 Q4 | 1.53 Billion USD | 96.3% |
| 2004 Q3 | 784 Million USD | -0.63% |
| 2003 Q4 | 194 Million USD | -17.45% |
| 2003 Q1 | 367 Million USD | 4.56% |
| 2003 Q2 | 285 Million USD | -22.34% |
| 2003 Q3 | 235 Million USD | -17.54% |
| 2002 Q3 | 693.4 Million USD | 0.0% |
| 2002 FY | 285 Million USD | 0.0% |
| 2002 Q4 | 351 Million USD | -49.38% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | 257.539% |
| Alpha Teknova, Inc. | 1.97 Million USD | 246.982% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | 103.08% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | 103.871% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 100.666% |
| Cosmos Health Inc. | 8.59 Million USD | 133.774% |
| Journey Medical Corporation | -9.7 Million USD | 70.116% |
| Embecta Corp. | 1.31 Billion USD | 100.221% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 100.633% |
| Dynavax Technologies Corporation | 106.63 Million USD | 102.721% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 97.782% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 100.67% |
| PainReform Ltd. | -7.95 Million USD | 63.504% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 81.442% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 81.442% |
| SCYNEXIS, Inc. | -19.35 Million USD | 85.006% |
| Safety Shot Inc | -2.28 Million USD | -27.012% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 69.231% |
| Procaps Group, S.A. | 242.93 Million USD | 101.194% |
| Theratechnologies Inc. | 24.87 Million USD | 111.666% |
| Harrow Health, Inc. | 116.41 Million USD | 102.492% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -15.136% |
| Biofrontera Inc. | 4.05 Million USD | 171.534% |
| DURECT Corporation | -7.65 Million USD | 62.093% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 91.346% |
| Cronos Group Inc. | -663.32 Million USD | 99.563% |
| OptiNose, Inc. | 58.06 Million USD | 104.997% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 100.465% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 80.089% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 44.053% |
| Organogenesis Holdings Inc. | 15.01 Million USD | 119.326% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 54.378% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 2815.193% |
| Radius Health, Inc. | 359.28 Million USD | 100.808% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | 1571.245% |
| ProPhase Labs, Inc. | 19.23 Million USD | 115.087% |
| Phibro Animal Health Corporation | 454.84 Million USD | 100.638% |
| Procaps Group S.A. | 242.93 Million USD | 101.194% |
| Alvotech | 1.06 Billion USD | 100.273% |
| TherapeuticsMD, Inc. | 3.67 Million USD | 178.886% |
| Viatris Inc. | 17.13 Billion USD | 100.017% |
| Rockwell Medical, Inc. | 4.45 Million USD | 165.113% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 40.508% |
| SIGA Technologies, Inc. | -148.68 Million USD | 98.049% |
| Tilray Brands, Inc. | 158.97 Million USD | 101.825% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 102.38% |
| Shineco, Inc. | 29.29 Million USD | 109.906% |
| PetIQ, Inc. | 351.93 Million USD | 100.824% |
| Incannex Healthcare Limited | -5.48 Million USD | 47.102% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 101.636% |
| Alimera Sciences, Inc. | 55.3 Million USD | 105.246% |
| Silver Spike Investment Corp. | -32.61 Million USD | 91.103% |
| Assertio Holdings, Inc. | -32.52 Million USD | 91.08% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -94.894% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 42.664% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 39.729% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 64.675% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | 168.803% |
| Hempacco Co., Inc. | 13.61 Million USD | 121.311% |
| Talphera, Inc. | -5.72 Million USD | 49.285% |
| Alvotech | 1.06 Billion USD | 100.273% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | 140.608% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 97.0% |
| Currenc Group, Inc. | -16.57 Million USD | 82.493% |
| Kamada Ltd. | -46.43 Million USD | 93.751% |
| Indivior PLC | -33.95 Million USD | 91.454% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | 1213.476% |
| Flora Growth Corp. | -713 Thousand USD | -306.932% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 64.675% |
| Evolus, Inc. | 63.7 Million USD | 104.554% |
| HUTCHMED (China) Limited | -197.45 Million USD | 98.531% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 100.606% |
| Akanda Corp. | 3.9 Million USD | 174.302% |